SWOG 1815: A phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers

Rachna T. Shroff, et al.

NAPOLI 3: A randomized, open-label phase 3 study of liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma

Zev A. Wainberg, et al.

Zolbetuximab + mFOLFOX6 as 1L treatment for patients with CLDN18.2+/HER2- locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary phase 3 results from SPOTLIGHT

Kohei Shitara, et al.

Nivolumab plus chemotherapy vs chemotherapy as first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma: 3-year follow-up from CheckMate 649

Yelena Y. Janjigian, et al.

Modified(m)-FOLFOXIRI plus cetuximab versus m-FOLFOXIRI plus bevacizumab as initial treatment of patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer: Survival analysis of the phase II randomized DEEPER trial by JACCRO

Yu Sunakawa, et al.

Trifluridine/tipiracil plus bevacizumab for third-line treatment of refractory metastatic colorectal cancer: The phase 3 randomized SUNLIGHT study

Josep Tabernero, et al.

Negative hyperselection of patients with RAS wild-type metastatic colorectal cancer for panitumumab: A biomarker study of the phase III PARADIGM trial

Kohei Shitara, et al.

HERIZON: A phase 2 study of HER-Vaxx (IMU-131), a HER2 targeting peptide vaccine, plus standard of care chemotherapy in patients with HER2 overexpressing metastatic or advanced gastric/GEJ adenocarcinoma. Final overall survival analysis

Tanuj Chawla, et al.

INTEGRATE IIa: Randomised double-blind phase III study of regorafenib versus placebo in refractory advanced gastro-oesophageal cancer (AGOC)

Nick Pavlakis, et al.